ScinoPharm Taiwan, Ltd.
1789.TW
Price:
$17.3
Market Cap:
$13.68B
ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells cGMP active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, and internationally. The company offers custom synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; and outsourcing services. It also provides CRAM services, such as chemistry skill, analytical and regulatory, chemical process development, clinical drug substance, and consulting services for the development and manufacturing of clinical, small-scale, and commercial-stage APIs and intermediates. In...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2011-09-29
Stock Exchange
TAI
Ticker
1789.TW
PE Ratio
[72.08]
ROE
[1.82%]
Current Ratio
[7.85]
Dividend Yield
[2.02%]
Enterprise Value
[11.60B]
Dividend History
The Enterprise Value as of December 2025 (TTM) for ScinoPharm Taiwan, Ltd. (1789.TW) is 11.60B
According to ScinoPharm Taiwan, Ltd.’s latest financial reports and current stock price. The company's current Enterprise Value is 11.60B. This represents a change of -11.98% compared to the average of 13.18B of the last 4 quarters.
ScinoPharm Taiwan, Ltd. (1789.TW) Historical Enterprise Value (quarterly & annually)
How has 1789.TW Enterprise Value performed in the past?
The mean historical Enterprise Value of ScinoPharm Taiwan, Ltd. over the last ten years is 21.05B. The current 11.60B Enterprise Value has changed 5.41% with respect to the historical average. Over the past ten years (40 quarters), 1789.TW's Enterprise Value was at its highest in in the December 2015 quarter at 39.81B. The Enterprise Value was at its lowest in in the June 2025 quarter at 12.17B.
Average
21.05B
Median
17.96B
Minimum
13.95B
Maximum
38.70B
ScinoPharm Taiwan, Ltd. (1789.TW) Enterprise Value by Quarter and Year
Discovering the peaks and valleys of ScinoPharm Taiwan, Ltd. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 13.00%
Maximum Annual Enterprise Value = 38.70B
Minimum Annual Increase = -37.93%
Minimum Annual Enterprise Value = 13.95B
| Year | Enterprise Value | Change |
|---|---|---|
| 2024 | 13.95B | -20.26% |
| 2023 | 17.49B | 5.96% |
| 2022 | 16.51B | 3.38% |
| 2021 | 15.97B | -17.41% |
| 2020 | 19.34B | 4.94% |
| 2019 | 18.43B | 13.00% |
| 2018 | 16.31B | -37.93% |
| 2017 | 26.27B | -4.71% |
| 2016 | 27.57B | -28.76% |
| 2015 | 38.70B | -0.38% |
ScinoPharm Taiwan, Ltd. (1789.TW) Average Enterprise Value
How has 1789.TW Enterprise Value performed in the past?
The current Enterprise Value of ScinoPharm Taiwan, Ltd. (1789.TW) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
15.98B
5-year avg
16.65B
10-year avg
21.05B
ScinoPharm Taiwan, Ltd. (1789.TW) Enterprise Value vs. Peers
How is 1789.TW’s Enterprise Value compared to its peers?
ScinoPharm Taiwan, Ltd.’s Enterprise Value is less than YungShin Global Holding Corporation (14.91B), less than Foresee Pharmaceuticals Co., Ltd. (12.18B), less than Ever Supreme Bio Technology Co., Ltd (14.20B), less than Synmosa Biopharma Corporation (17.75B), greater than Standard Chem & Pharm Co. Ltd. (10.36B), greater than Visco Vision Inc. (10.95B), less than Excelsior Medical Co., Ltd. (13.51B), less than United Orthopedic Corporation (12.80B), less than Tanvex BioPharma, Inc. (17.07B), less than Grape King Bio Ltd (15.82B),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 14.91B | $14.97B | |
| 12.18B | $12.69B | |
| 14.20B | $14.37B | |
| 17.75B | $16.05B | |
| 10.36B | $10.76B | |
| 10.95B | $11.09B | |
| 13.51B | $13.98B | |
| 12.80B | $11.43B | |
| 17.07B | $16.10B | |
| 15.82B | $18.74B |
Build a custom stock screener for ScinoPharm Taiwan, Ltd. (1789.TW) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ScinoPharm Taiwan, Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
ScinoPharm Taiwan, Ltd. (1789.TW) and other stocks custom spreadsheet templates
The easiest way to analyze a company like ScinoPharm Taiwan, Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the Enterprise Value?
How can you use the Enterprise Value?
What is ScinoPharm Taiwan, Ltd.'s Enterprise Value?
What is the highest Enterprise Value for ScinoPharm Taiwan, Ltd. (1789.TW)?
What is the 3-year average Enterprise Value for ScinoPharm Taiwan, Ltd. (1789.TW)?
What is the 5-year average Enterprise Value for ScinoPharm Taiwan, Ltd. (1789.TW)?
How does the current Enterprise Value for ScinoPharm Taiwan, Ltd. (1789.TW) compare to its historical average?